Human monoclonal antibodies specific for glypican-3 and use thereof

A human monoclonal antibody, phosphatidylinositol technology, applied in the direction of antibodies, immunoglobulins, antibody medical components, etc., can solve the problem that the molecular mechanism of tumor metastasis is poorly understood.

Active Publication Date: 2014-02-19
UNITED STATES OF AMERICA
View PDF36 Cites 22 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Tumor metastasis is a major cause of cancer-related death, but the molecular mechanisms underlying tumor metastasis remain poorly understood

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Human monoclonal antibodies specific for glypican-3 and use thereof
  • Human monoclonal antibodies specific for glypican-3 and use thereof
  • Human monoclonal antibodies specific for glypican-3 and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0315] Example 1: HN3—a human single-domain monoclonal antibody that binds cell surface-associated Glypican 3 and inhibits HCC cell proliferation

[0316] This example describes the generation and characterization of high affinity single domain mAbs against tumor-associated GPC3.

[0317] A. Materials and methods

[0318] cell line

[0319] Human hepatoma cell lines HepG2, Hep3B, HuH-1, HuH-4, HuH-7 and SK-Hep1 were maintained in adherent monolayer cultures supplemented with 10% fetal bovine serum (HyClone, Logan, UT), 1% L-glutamine and 1% penicillin-streptomycin (Invitrogen, Carlsbad, CA) in D-MEM medium (Invitrogen, Carlsbad, CA) at 37 °C in 5% CO 2 incubate in air. Cells were harvested and the medium was changed twice a week. Cells were confirmed to be mycoplasma negative. The GPC3-negative cell line A431 (a human epithelial carcinoma cell line) was engineered to express high levels of GPC3 by transfection with a plasmid encoding GPC3. Both A431 and a stably transfec...

Embodiment 2

[0355] Example 2: HS20—a human monoclonal antibody that binds heparan sulfate chains on GPC3 and inhibits the migration of hepatocellular carcinoma cells

[0356] This example describes the generation and characterization of human mAbs that bind heparan sulfate on GPC3.

[0357] A. Materials and methods

[0358] cell line

[0359] A panel of six human HCC cell lines (SK-Hep1, HepG2, Hep3B, Huh-1, Huh-4, and Huh-7) was obtained from the Human Carcinogenesis Laboratory, National Cancer Institute (NCI), Bethesda, MD (National Cancer Institute (NCI) Laboratory of Human Carcinogenesis, Bethesda, Maryland). A431 (human epithelial carcinoma cell line) was obtained from the American Type Culture Collection (ATCC; Manassas, VA). The cell lines were cultured in RPMI or DMEM supplemented with 10% fetal bovine serum, 100 U / mL penicillin, 0.1 mg / mL streptomycin, and 2 mmol / L L-glutamine. Cells were harvested and the medium was changed twice a week. Cells were confirmed to be mycoplasm...

Embodiment 3

[0402] Example 3: Mutation of HS20 to remove N-glycosylation sites does not alter affinity and specificity

[0403] This example describes the modification of the H220 mAb to remove the N-glycosylation sites identified in the VL domain.

[0404] Two light chain bands were observed in HS20 IgG expressed in a HEK-293-based mammalian expression system, suggesting the presence of N-glycosylation sites. By analyzing the sequence of the light chain, a possible N-glycosylation site was identified in CDR2 of the VL domain of HS20 (amino acid residue 50 in SEQ ID NO: 16). The presence of N-glycosylation sites produced an additional band of approximately 30 kDa when analyzed by SDS-PAGE; however, when purified HS20 IgG was treated with the endoglycosidase PNGase to remove all N-glycosylation , a single band was observed (Fig. 15A). Western blot of H2S0 mAb treated with PNGase also demonstrated a single VL band, whereas untreated antibody produced two bands of the VL domain (Fig. 15B)....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
molecular weightaaaaaaaaaa
Login to view more

Abstract

Described herein is the identification of human monoclonal antibodies that bind GPC3 or heparan sulfate (HS) chains on GPC3 with high affinity. The antibodies described herein are capable of inhibiting HCC cell growth and migration. Provided are human monoclonal antibodies specific for GPC3 or HS chains on GPC3, including immunoglobulin molecules, such as IgG antibodies, as well as antibody fragments, such as single-domain VH antibodies or single chain variable fragments (scFv). Further provided are compositions including the antibodies that bind GPC3 or HS chains on GPC3, nucleic acid molecules encoding these antibodies, expression vectors comprising the nucleic acids, and isolated host cells that express the nucleic acids. Methods of treating cancer and / or inhibiting tumor growth or metastasis are also provided. Further provided are methods of detecting cancer in a subject and confirming a diagnosis of cancer in a subject.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of US Provisional Application No. 61 / 477,020, filed April 19, 2011, which is incorporated herein by reference in its entirety. technical field [0003] The present disclosure relates to antibodies specific for Glypican 3 (GPC3) or heparan sulfate on GPC3 and their use for the treatment of cancer. Background technique [0004] Liver cancer is the fifth most prevalent tumor and the third most common cause of cancer-related death in the world (Bosch et al., Gastroenterology 127:S5-S16, 2004; El-Serag et al., Gastroenterology 132: 2557-76, 2007). According to the American Cancer Society, hepatocellular carcinoma (HCC) accounts for approximately 75 percent of liver cancer cases. Symptoms often do not appear until advanced liver cancer. Surgery is the standard treatment for liver cancer because this type of cancer does not respond well to most chemotherapy drugs. Therefore, there is an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/30
CPCA61K39/39558C07K2317/33C07K2319/00C07K2317/569C07K16/3092G01N33/6893C07K2317/92C07K2317/21C07K16/303A61K2039/505C07K2317/41C07K2317/73A61K35/17G01N33/57438G01N2400/40A61K47/6829A61K47/6849A61P35/00C07K16/28C07K2317/56C07K2317/622C07K14/21C07K16/3076C07K2317/31C07K2317/565C07K2319/33C07K2319/55G01N33/57492G01N2333/705A61K47/6851A61K47/6803A61K47/6813
Inventor M·何丰明乾W·高金兴男D·S·迪米特洛夫
Owner UNITED STATES OF AMERICA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap